Amitkumar Mehta
Hematology & Oncology · Birmingham, ALNPI 1003122573
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.8%. 2025 is the largest year on record at $150,368, 2.0 times the $73,498 reported in 2019. Among hematology & oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 449 payments — averaging $1521.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$156K
- ADC Therapeutics America, Inc.$81K
- AstraZeneca$70K
- Gilead$64K
- E.r. Squibb & Sons, L.L.C.$54K
- Beigene USA, Inc.$45K
- plus $214K from 27 others
Across 1,490 payments — averaging $11,998 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3.5M
- Kyowa Kirin, Inc.$3.2M
- Genentech, Inc.$2.8M
- Takeda Pharmaceuticals U.S.A., Inc.$2.6M
- Incyte Corporation$1.7M
- Pfizer$1M
- plus $3M from 17 others
What the payments were for
- Consulting fees$285,68742%
- Speaking & faculty fees$350,85351%
- Travel & lodging$40,1356%
- Food & beverage$6,2501%
- Education$3830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 87 | $155,536 |
| ADC Therapeutics America, Inc. | 35 | $80,703 |
| AstraZeneca | 39 | $70,053 |
| Gilead(2 entities) | 52 | $64,312 |
| E.r. Squibb & Sons, L.L.C. | 19 | $53,715 |
| Beigene USA, Inc. | 26 | $44,977 |
| Genentech USA, Inc. | 33 | $40,327 |
| Seagen Inc. | 32 | $38,884 |
| Kyowa Kirin, Inc. | 21 | $22,806 |
| Novartis | 11 | $17,538 |
| Bristol Myers Squibb | 13 | $15,912 |
| Morphosys, US Inc. | 10 | $11,874 |
| Pharmacyclics LLC, An Abbvie Company | 20 | $7,611 |
| Epizyme, Inc. | 6 | $7,189 |
| Janssen Scientific Affairs, LLC | 6 | $6,131 |
| Imbrium Therapeutics L.p. | 1 | $5,568 |
| Otsuka Pharmaceutical Co., Ltd. | 2 | $4,997 |
| Adaptive Biotechnologies Corporation | 4 | $4,450 |
| Johnson & Johnson | 5 | $3,968 |
| Genmab U.S., Inc. | 3 | $2,940 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,610 |
| Pfizer | 2 | $2,520 |
| Cardinal Health 105 LLC | 3 | $2,296 |
| Daiichi Sankyo Inc. | 1 | $2,096 |
| Genentech, Inc. | 2 | $2,075 |
| Astrazeneca UK Limited | 1 | $2,050 |
| Karyopharm Therapeutics Inc. | 1 | $1,938 |
| TG Therapeutics, Inc. | 1 | $1,856 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,650 |
| F. Hoffmann-la Roche AG | 2 | $1,626 |
| Beigene, Ltd. | 2 | $1,321 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,000 |
| AbbVie | 6 | $781 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$683,308 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 107 | $1,293,100 |
| ImbruvicaIbrutinib | 71 | $1,021,571 |
| VenclextaVenetoclax | 61 | $491,911 |
| BrukinsaZanubrutinib | 39 | $451,949 |
| JaypircaPirtobrutinib | 20 | $414,458 |
| RevlimidLenalidomide | 21 | $336,714 |
| Lenalidomide | 18 | $241,744 |
| CopiktraDuvelisib | 15 | $205,242 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 22 | $124,634 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 29 | $123,052 |
| Acyclovir | 208 | $2,281 |
| Dapsone | 20 | $1,161 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $748 |
| Gabapentin | 40 | $669 |
| Dexamethasone | 37 | $498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $70,053 | $1,293,100107 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $7,611 | $1,021,57171 claims |
| AbbVieVenclexta | $781 | $491,91161 claims |
| Beigene USA, Inc.Brukinsa | $44,977 | $451,94939 claims |
| Bristol Myers SquibbRevlimid | $15,912 | $336,71421 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,650 | $123,05229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
- Christos VaklavasBirmingham$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.